The work of two faculty members at the University at Buffalo (UB), Jacob School of Medicine and Biomedical Sciences — Danielle M. Goetz, MD, and Carla A. Frederick, MD — were instrumental in the research that led to the approval of Symdeko (tezacaftor/ivacaftor and ivacaftor) for the treatment of…
News
Vertex Pharmaceuticals announced the opening of a 170,000-square-foot research facility in San Diego, representing a significant expansion of its research presence in the area. The San Diego site is one of Vertex’s three research hubs where the company’s approved, three disease-modifying cystic fibrosis (CF) medicines were discovered. More than 70…
The University of North Carolina (UNC) is among only a few institutions in the United States that offers patients with inflamed pancreas (pancreatitis) or pancreatic cystosis a surgical treatment option that allows a better outcome. It is relatively common for patients with cystic fibrosis (CF) to develop small cysts in…
SPX-101, designed to help clear mucus from the lungs of people with cystic fibrosis, has the potential to treat all CF patients — regardless of disease-causing mutations. The experimental peptide, which blocks the overactive sodium channels that line CF lung cells so more fluids are retained on airway surfaces to hydrate mucus,…
The Adult Cystic Fibrosis Program at West Virginia University Medicine’s Mountain State Cystic Fibrosis Center was recently awarded accreditation from the Cystic Fibrosis Foundation (CFF) for its work in the cystic fibrosis (CF) community. The accreditation is granted to institutions after a thorough application process that includes a site visit, interviews…
Some 318,000 health-related software apps are now on the market, with another 200 appearing every day. Yet a British cystic fibrosis expert questions how effective they are at managing lung disease, for reasons that range from the needless anxiety they can cause to sporadic use and concerns with patient data protection.
Vertex Pharmaceuticals employees have raised more million $1 million using the Vertex Foundation‘s matching gift program in a show of commitment to causes that include the cystic fibrosis (CF) community, a company press release states. The dollar-for-dollar matching gift program is being run through the nonprofit Vertex Foundation, established by the company…
Vertex Pharmaceuticals’ treatments for cystic fibrosis (CF) all provide considerable benefits, but their pricing is not transparent and does not align with the medications clinical value, a review of the Institute for Clinical and Economic Review (ICER)’s report by the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC)…
New research provides insights into how bacteria “talk” to each other in lung infections, which could provide strategies to block these signals and ease bacterial virulence in patients with cystic fibrosis (CF). The study, “Spatial determinants of quorum signaling in a Pseudomonas aeruginosa infection model,” was…
Combining the approved multiple sclerosis treatment glatiramer acetate with the antibiotic tobramycin improved its ability to kill antibiotic-resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis (CF) patients, new data show. These results were shared in the presentation “The repurposed multiple sclerosis drug, glatiramer acetate, is an antibiotic resistance breaker in Pseudomonas aeruginosa…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.